VEGFA and glioblastoma: The combined administration of temsirolimus and sorafenib (a RAS, VEGF, and PDGF inhibitor) did not improve survival in recurrent GBM patients either (mean PFS was 8 weeks and progression-free patients at 6 months was 0%) [275].